Literature DB >> 28611041

An Immunosuppressive Dendritic Cell Subset Accumulates at Secondary Sites and Promotes Metastasis in Pancreatic Cancer.

Justin A Kenkel1, William W Tseng1, Matthew G Davidson1, Lorna L Tolentino1, Okmi Choi1, Nupur Bhattacharya1, E Scott Seeley1, Daniel A Winer1, Nathan E Reticker-Flynn1, Edgar G Engleman2.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) after complete surgical resection is often followed by distant metastatic relapse for reasons that remain unclear. In this study, we investigated how the immune response at secondary sites affects tumor spread in murine models of metastatic PDAC. Early metastases were associated with dense networks of CD11b+CD11c+MHC-II+CD24+CD64lowF4/80low dendritic cells (DC), which developed from monocytes in response to tumor-released GM-CSF. These cells uniquely expressed MGL2 and PD-L2 in the metastatic microenvironment and preferentially induced the expansion of T regulatory cells (Treg) in vitro and in vivo Targeted depletion of this DC population in Mgl2DTR hosts activated cytotoxic lymphocytes, reduced Tregs, and inhibited metastasis development. Moreover, blocking PD-L2 selectively activated CD8 T cells at secondary sites and suppressed metastasis, suggesting that the DCs use this particular pathway to inhibit CD8 T-cell-mediated tumor immunity. Phenotypically similar DCs accumulated at primary and secondary sites in other models and in human PDAC. These studies suggest that a discrete DC subset both expands Tregs and suppresses CD8 T cells to establish an immunosuppressive microenvironment conducive to metastasis formation. Therapeutic strategies to block the accumulation and immunosuppressive activity of such cells may help prevent PDAC progression and metastatic relapse after surgical resection. Cancer Res; 77(15); 4158-70. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2017        PMID: 28611041      PMCID: PMC5550516          DOI: 10.1158/0008-5472.CAN-16-2212

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity.

Authors:  Miranda L Broz; Mikhail Binnewies; Bijan Boldajipour; Amanda E Nelson; Joshua L Pollack; David J Erle; Andrea Barczak; Michael D Rosenblum; Adil Daud; Diane L Barber; Sebastian Amigorena; Laura J Van't Veer; Anne I Sperling; Denise M Wolf; Matthew F Krummel
Journal:  Cancer Cell       Date:  2014-10-16       Impact factor: 31.743

Review 2.  The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting.

Authors:  Miriam Merad; Priyanka Sathe; Julie Helft; Jennifer Miller; Arthur Mortha
Journal:  Annu Rev Immunol       Date:  2013       Impact factor: 28.527

3.  Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer.

Authors:  Marina Lesina; Magdalena U Kurkowski; Katharina Ludes; Stefan Rose-John; Matthias Treiber; Günter Klöppel; Akihiko Yoshimura; Wolfgang Reindl; Bence Sipos; Shizuo Akira; Roland M Schmid; Hana Algül
Journal:  Cancer Cell       Date:  2011-04-12       Impact factor: 31.743

4.  Dendritic cells induce regulatory T cell proliferation through antigen-dependent and -independent interactions.

Authors:  Tao Zou; Andrew J Caton; Gary A Koretzky; Taku Kambayashi
Journal:  J Immunol       Date:  2010-08-04       Impact factor: 5.422

5.  Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells.

Authors:  Angela M Thornton; Patricia E Korty; Dat Q Tran; Elizabeth A Wohlfert; Patrick E Murray; Yasmine Belkaid; Ethan M Shevach
Journal:  J Immunol       Date:  2010-02-24       Impact factor: 5.422

6.  CD301b⁺ dermal dendritic cells drive T helper 2 cell-mediated immunity.

Authors:  Yosuke Kumamoto; Melissa Linehan; Jason S Weinstein; Brian J Laidlaw; Joseph E Craft; Akiko Iwasaki
Journal:  Immunity       Date:  2013-09-26       Impact factor: 31.745

7.  Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.

Authors:  Nobuyoshi Hiraoka; Kaoru Onozato; Tomoo Kosuge; Setsuo Hirohashi
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

Review 8.  Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage.

Authors:  Sergei I Grivennikov; Michael Karin
Journal:  Ann Rheum Dis       Date:  2011-03       Impact factor: 19.103

9.  Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.

Authors:  Dung T Le; Eric Lutz; Jennifer N Uram; Elizabeth A Sugar; Beth Onners; Sara Solt; Lei Zheng; Luis A Diaz; Ross C Donehower; Elizabeth M Jaffee; Daniel A Laheru
Journal:  J Immunother       Date:  2013-09       Impact factor: 4.456

10.  The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity.

Authors:  Damya Laoui; Jiri Keirsse; Yannick Morias; Eva Van Overmeire; Xenia Geeraerts; Yvon Elkrim; Mate Kiss; Evangelia Bolli; Qods Lahmar; Dorine Sichien; Jens Serneels; Charlotte L Scott; Louis Boon; Patrick De Baetselier; Massimiliano Mazzone; Martin Guilliams; Jo A Van Ginderachter
Journal:  Nat Commun       Date:  2016-12-23       Impact factor: 14.919

View more
  42 in total

Review 1.  Kras and Tumor Immunity: Friend or Foe?

Authors:  Jane Cullis; Shipra Das; Dafna Bar-Sagi
Journal:  Cold Spring Harb Perspect Med       Date:  2018-09-04       Impact factor: 6.915

2.  Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes.

Authors:  Nadine Santana-Magal; Diana Rasoulouniriana; Corey Saperia; Amit Gutwillig; Peleg Rider; Edgar G Engleman; Yaron Carmi
Journal:  J Vis Exp       Date:  2018-05-31       Impact factor: 1.355

3.  ACTR3 promotes cell migration and invasion by inducing epithelial mesenchymal transition in pancreatic ductal adenocarcinoma.

Authors:  Hao Hu; Shuo Zhang; Shuming Xiong; Benshun Hu; Youzhao He; Yuanlong Gu
Journal:  J Gastrointest Oncol       Date:  2021-10

4.  Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer.

Authors:  Samarth Hegde; Varintra E Krisnawan; Brett H Herzog; Chong Zuo; Marcus A Breden; Brett L Knolhoff; Graham D Hogg; Jack P Tang; John M Baer; Cedric Mpoy; Kyung Bae Lee; Katherine A Alexander; Buck E Rogers; Kenneth M Murphy; William G Hawkins; Ryan C Fields; Carl J DeSelm; Julie K Schwarz; David G DeNardo
Journal:  Cancer Cell       Date:  2020-03-16       Impact factor: 31.743

Review 5.  Regulation and modulation of antitumor immunity in pancreatic cancer.

Authors:  Joshua Leinwand; George Miller
Journal:  Nat Immunol       Date:  2020-08-17       Impact factor: 25.606

Review 6.  Cancer systems immunology.

Authors:  Nathan E Reticker-Flynn; Edgar G Engleman
Journal:  Elife       Date:  2020-07-13       Impact factor: 8.140

Review 7.  Immune crosstalk in cancer progression and metastatic spread: a complex conversation.

Authors:  Hannah Garner; Karin E de Visser
Journal:  Nat Rev Immunol       Date:  2020-02-05       Impact factor: 53.106

Review 8.  Pancreatic cancer immune evasion mechanisms: the immunosuppressive role of P2RX1-negative neutrophils.

Authors:  Valentina Audrito
Journal:  Purinergic Signal       Date:  2021-03-30       Impact factor: 3.765

Review 9.  Cancer stem cell-immune cell crosstalk in tumour progression.

Authors:  Defne Bayik; Justin D Lathia
Journal:  Nat Rev Cancer       Date:  2021-06-08       Impact factor: 60.716

Review 10.  Myeloid Cells in Metastasis.

Authors:  Agnieszka Swierczak; Jeffrey W Pollard
Journal:  Cold Spring Harb Perspect Med       Date:  2020-05-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.